Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib
Abstract Previous studies demonstrated codon-specific KRAS mutation as a potential biomarker of resistance in metastatic colorectal cancer (mCRC). Our study aimed to evaluate the association of RAS status on survival in patients with mCRC treated with trifluridine/tipiracil (FTD/TPI) or regorafenib....
שמור ב:
| Principais autores: | , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Portfolio
2026-01-01
|
| סדרה: | Scientific Reports |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1038/s41598-026-36509-y |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|